MedTrace Logo

Generic Plerixafor Efficacy of Autologous Hematopoietic Stem Cell Transplantation

NCT06892119 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2025-03-27

No results posted yet for this study

Summary

Generic plerixafor use at reduced-dose for mobilization on HSCT transplant

Conditions

Interventions

DRUG

Celrixafor

Use a reduced-dose of generic plerixafor

Sponsors & Collaborators

  • Hospital Universitario Dr. Jose E. Gonzalez

    lead OTHER

Principal Investigators

  • Olga G Cantú-Rodríguez, MD · Universidad Autónoma de Nuevo León

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-12-09
Primary Completion
2020-11-30
Completion
2020-11-30

Countries

  • Mexico

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06892119 on ClinicalTrials.gov